427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. - Moek, K L; Fiedler, W M; Einem, J C von; Verheul, H M; Seufferlein, T; Groot, D J de; Heinemann, V; Kebenko, M; Oordt, C W Menke-van der Houven van; Ettrich, T J (Annals of Oncology, 2018)